Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADR  by Khan, Lateef M. et al.
Saudi Pharmaceutical Journal (2013) 21, 261–266King Saud University
Saudi Pharmaceutical Journal
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLEAdverse drug reactions in hospitalized pediatric
patients of Saudi Arabian University Hospital
and impact of pharmacovigilance in reporting ADR* Corresponding author. Address: Department of Pharmacology,
College ofMedicine,KingAbdulazizUniversity, P.O.Box 80205, Jeddah
21589, Saudi Arabia. Tel.: +966 508267914; fax: +966 26408404.
E-mail address: lmkhan00@hotmail.com (L.M. Khan).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
1319-0164 ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.jsps.2012.09.004Lateef M. Khan a,*, Sameer E. Al-Harthi a, Omar I. Saadah ba Department of Pharmacology, College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
b Department of Pediatrics, College of Medicine, King Abdulaziz University, Jeddah, Saudi ArabiaReceived 30 July 2012; accepted 11 September 2012
Available online 6 October 2012KEYWORDS
Adverse drug reactions;
ADR monitoring;
Hospitalized patients;
PharmacovigilanceAbstract Objectives: Children are more vulnerable to ADRs, and this susceptibility is com-
pounded due to hospitalization. There is a lack of local data regarding the potential risk of ADRs
in hospitalized pediatric patients. Therefore, this study is designed to identify the frequent nature,
severity of adverse drug reactions, drugs implicated and factors inﬂuencing ADRs.
Methods: Intensive monitoring study of ADRs was done in hospitalized pediatric patients of
King Abdulaziz University Hospital, Jeddah from January to December 2011, with an analogous
retrospective study for the preceding year to determine incidence rate, demographic aspects, causal-
ity appraisal, polypharmacy, body organs/systems involved and drugs implicated in ADR. Compar-
ison of the two data was done to determine the impact of pharmacovigilance.
Results: Incidence rate of ADRs in retrospective study was (4.50%) and (8.2%) in prospective
study. ADR was more in patients who received 5–6 drugs, which was (15.5%) in retrospective study
and (22.1%) in prospective study.Regarding age, it was the highest in patients of 0–1 year of agewhich
was (40.7%) in retrospective study and (38.8%) in prospective study. Anti-infective agents were the
most frequently involved in ADR (40.8%) in prospective study and (48.2%) and retrospective study.
This study also demonstrated that, there was high susceptibility of the skin to the ADR which was
(37%) in retrospective study and (42.9%) in prospective study. None of the ADRs proved to be fatal.
Conclusion: Well premeditated intensive monitoring approach in pharmacovigilance ampliﬁes the
ADR detection, which can persuade healthcare providers into more drug safety.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Science of pharmacovigilance is accountable to identify, ap-
praise, comprehend and avert ADRs with the eventual mean
to develop secure and coherent utilization of medication
(Montastruc et al., 2006; Arulmani et al., 2008; Avery et al.,
2011; Mehta et al., 2008). Current methods of pharmacovigi-
lance possess certain constraints reminiscent of under reporting,
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exposed and bias in collection of drug exposure (Montastruc
et al., 2006; Wasserfallen et al., 2001; Routledge et al., 2003;
Smyth et al., 2012). Pharmacovigilance gives a vital measure
of the burden of drug induced morbidity and approximately
half of ADRs could be averted with better prescription care
(Chien and Ho, 2011; Aagaard and Hansen, 2010; Napoleone,
2010).
Most recent review of ADRs reported incidence of hospital-
ized ADRs in children in the range of 0.6–16.8% (Smyth et al.,
2012). Children are at a higher risk of developing ADRs as
they seldom express their own drug therapy experiences
(Castro-Pastrana and Carleton, 2011). Consequently, medica-
tions in pediatrics have a risk of a variety of ADRs (Castro-
Pastrana and Carleton, 2011; Impicciatore, 2003). This reality
describes children as ‘‘therapeutic orphan’’ and they are at a
precarious position of a high risk of therapeutic failure with
additional vulnerabilities like lack of many appropriate pediat-
ric formulations, exposure through maternal prenatal drug use
and breast milk, major difference in pharmacokinetic, pharma-
codynamics of drugs, ‘‘off-label use’’ and perhaps divergence
of their illness from adult (Chien and Ho, 2011; Napoleone,
2010; Impicciatore, 2003; Leeder, 2003; Lindell-Osuagwu
et al., 2009). There is an urgent need for evolving valuable
methods for the early detection of ADRs in pediatrics hitherto
their necessary stipulation of pharmacovigilance has not been
tackled appropriately (Castro-Pastrana and Carleton, 2011)
(Etwel et al., 2008).
Few local studies correlated to community acquired ADR
and clinical pharmacist intervention in intensive care unit that
were reported (Al-Malaq et al., 2008; Al-Jazairi et al., 2008;
Al-Olah and Al Thiab, 2008), and a study of attitude and
behavior of hospital pharmacist toward reporting ADRs in
Saudi Arabian hospital (AlSultan and Bawazir, 2009), whereas
no study was found related to ADRs in hospitalized pediatric
or adult patients. The intention of this paper is to study hospi-
tal acquired ADR by an intensive monitoring method and, to
recognize and describe the pattern of ADRs due to frequently
used drugs, this in turn may be useful to recognize and curtail
preventable ADRs which may have an impact on pediatric
drug safety.2. Methods
This study was planned to appraise the incidence, frequent nat-
ure of ADRs with reference to their severity in hospitalized pa-
tients of pediatric wards of King Abdulaziz University
Hospital and to corroborate the impact of pharmacovigilance
in reporting ADR.
Prospective observational study for monitoring ADR was
conducted in hospitalized patients of pediatric department,
King Abdulaziz University Hospital. This study was per-
formed from January–December 2011. A parallel retrospective
study was also taken on, by reviewing patient’s ﬁle for analysis
of ADRs during the last one year. Each study was conducted
by taking 600 patients. The sample size of 600 patients was
planned to perceive an incidence rate of 6.7% found in an
international systematic review (Wiffen et al., 2002).
Study protocol was approved by institutional ethics com-
mittee. Discretion of information acquired was secured during
the study. Suitable study design for monitoring ADR wasdeveloped for data compilation and this was validated by
accomplishing a pilot study in 25 patients.
Exclusion criteria: duration of hospitalization less than
1 day, intake of drugs more or less than required (medication
error or non compliance). Inclusion criteria: All patients of
either sex between the ages 0–15 years admitted in pediatric
wards were included in the study. No untoward episode was
marked as ADR without the conformity of treating clinician.
All relevant data of drugs, type of ADR, preliminary data
of ADR suspected, drug causing ADR, body/system impli-
cated in ADR, number of drugs administered to each patient
and demographic information were scrutinized. Incidence rate
was calculated in both studies and evaluation of proportion of
total adverse drug reactions was done to ascertain signiﬁcant
differences in the incidence rate and impact of pharmacovigi-
lance by intensive monitoring of ADR.
Appraisal of the causality of ADR was done using
Naranjo’s algorithm scale. This is the most common assess-
ment tool of ADR, and veriﬁes the chances of whether an
ADR is essentially due to the drug or it is the result of other
causes, the likelihood is consigned by the score, termed as def-
inite, probable or possible (Naranjo et al., 1981). The severity
of ADRs was assessed by Hartwig’s scale. Examples of ADRs
assessed as severe are those that caused death, directly life-
threatening, lengthened hospitalization or shift to a higher
level of clinical care (Hartwig et al., 1992). ADRs were also
classiﬁed as either augmented or allergic/idiosyncratic
(Rawlins and Thompson, 1991).
2.1. Statistical analysis
Results are expressed in absolute number and percentages. The
data were analyzed and comparisons between incidence of
ADRs in both studies and in different age groups were exe-
cuted with Chi-square test. P< 0.05 is considered signiﬁcant.
2.2. Results
In retrospective study (4.5%) patients developed ADR, com-
pared to (8.2%) patients in prospective study (Table 1).
The causality assessment in prospective study divulge that
most of the ADRs belong to possible 23 (46.9%), followed
by probable 22 (44.9%) and deﬁnite 4 (8.2%). However, in ret-
rospective study ADR pattern was, possible 13 (48.2%), prob-
able 12 (44.4%) and deﬁnite 2 (7.4%) (Table 1). Regarding
type of ADRs, 33 out of 49 ADRs in prospective study, were
type A reactions (augmented) and 16 were type B reactions (Bi-
zarre), whereas in retrospective study they were 19 and 8
respectively (Table 1).
All patients in both studies were divided in three groups
according to the number of drugs consumed by them. The
crest incidence of ADRs (15.5%) in retrospective study and
(22.1%) in prospective study is observed in both groups receiv-
ing 5–6 drugs (Table 2).
In both retrospective and prospective studies, all patients
were divided into four age groups. The incidence of ADRs
was the highest in patients of age 0–1 year in both prospective
(40.7%) and retrospective studies (38.8%) and it was found to
be statistically signiﬁcant in both studies (Fig. 1).
In prospective and retrospective studies within group anal-
ysis, comparing the frequency of ADRs between patients less
Table 1 Causality, incidence, and type of adverse drug reactions in 600 patients of both retrospective and prospective studies.
Retrospective study Prospective study
Character Male n (%) Female n (%) Total n (%) P Value Male n (%) Female n (%) Total n (%) P Value
Incidence 11(40.7) 16(59.3) 27(4.5)** 0.58§ 26(53.1) 23(46.9) 49(8.2)** 0.86§
Deﬁniteª 01(50) 01(50) 2(7.4) 1.00§ 01(33.3) 03(66.7) 4(8.2) 0.83§
Probableª 05(41.7) 07(58.3) 12(44.4) 0.90§ 9(40.9) 13(59.1) 22(44.9) 0.66§
Possibleª 07(53.8) 06(46.1) 13(48.2) 0.82§ 14(60.9) 09(39.1) 23(46.9) 0.55§
ADR type A 08(42.1) 11(57.9) 19(70.3) 0.77§ 14(42.4) 19(57.6) 33(67.3) 0.61§
ADR type B 3(37.5) 5(62.5) 08(29.6) 0.88§ 05(31.3) 11(68.7) 16(32.7) 0.35§
ª Causality evaluation of ADR.
§ No statistically signiﬁcant inﬂuence of gender was observed on ADR.
** The difference of ADR incidence between two studies was signiﬁcant (Chi-square 5.990, P< 0.05).
Table 2 Correlation of drug consumption and adverse drug
reaction in retrospective study and prospective studies.
Group of
patients
Number of
drugs
ADR n (%)
in retrospective study.
ADR n (%)
in prospective study
A 1–2 3(1.8) 7(4.0)
B 3–4 9(2.6) 19 (5.9)
C 5–6 15(15.5)* 23(22.1)§
§ Whereas in prospective study P value was > 0.0001.
* In retrospective study within group analysis of less than 5–6 drugs
and more than 5–6 drugs P value was < 0.05.
Table 4 Drugs most frequently implicated in ADR in
retrospective and prospective studies.
Drug class involved
in ADRs
Number of
ADRs (%) in
retrospective study
Number of
ADRs (%)in
prospective study
Anti-infective drugs 13(48.2) 20(40.9)
Anticancer Drugs 3(11.1) 3(6.1)
Anti-epileptic drugs 4(14.8) 8(16.3)
NSAIDs 2(7.4) 6(12.2)
Immunomodulators 0(00) 5(10.2)
Hormonal preparations 2(7.4) 6(12.2)
Diuretics 3(11.1) 1(2.1)
Total 27(100) 49(100)
Figure 1 Relationship of ADR to age in retrospective and
prospective studies.
Table 3 Frequency of systems implicated in ADR in retro-
spective and prospective studies.
Systems involved
in ADR
Number of
ADRs (%) in
retrospective study
Number of
ADRs (%) in
prospective study
Gastrointestinal 9(33.3) 12(24.5)
Skin and appendages 10(37) 21(42.9)
Central nervous system 2(7.4) 7(14.3)
Metabolic 2(7.4) 1(2.0)
Liver 1(3.8) 1(2.0)
Hematological 2(7.4) 4(8.2)
Multi-system 1(3.7) 3(6.1)
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lue was > 0.001 and < 0.05 respectively (See Table 2).
Skin associated ADRs were most frequent in both retro-
spective and prospective studies 37% and 42.9% followed by
gastrointestinal tract 33.3% and 24.5% respectively (Table 3).
Concerning patient medications, anti-infective drugs were
the more commonly implicated 40.9% in prospective study
and 48.2% in retrospective study followed by antiepileptic
drugs 16.3% in prospective study and 14.8% in retrospective
study (Table 4)..
3. Discussion
In this study the incidence rate of adverse drug reaction in ret-
rospective study was 4.5% and in prospective study it was
8.2%. There was a signiﬁcant difference between these twostudies (Chi-square = 5.990 and P< 0.05). In comparison,
our results are in the lower range of the most recent extensively
studied review of ADRs in pediatrics with a coverage span of
45 years and consist of 51 studies of hospitalized ADRs
(Smyth et al., 2012). The variation in incidence of ADRs
across the globe includes ethnic, genetic and dietary factors.
Other attributes could be difference in disease pattern, national
ﬁnancial class, healthcare infrastructure, local pharmaceutical
company promotion and most importantly the detection meth-
ods employed (Eliasson, 2006; Camargo et al., 2006; Demoly
and Bousquet, 2001). Yet, it could be due to the use of com-
puterized physician order entry (CPOE) system practiced in
our hospital which can probably reduce the medication error
rates; such practice had shown reduction of medication error
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2003). The present study is done on a small number of patients
and short duration could be the additional grounds.
Polypharmacy is an additive risk of drug–drug interaction
and important predictor of ADR (Smyth et al., 2012; Impiccia-
tore, 2003; (Priyadharsini et al., 2011). It is reported that 30% of
neonates receivingmore than 10 drugs get no less than oneADR
(Priyadharsini et al., 2011), exponential rise ofADRs in neonates
was seen when exposed to four or more medications, newborn
and infants are at a higher risk due to immature metabolizing
system (Kaushal et al., 2001). This is reﬂected in our study by
the signiﬁcant increase of ADRs with the use of 5–6 drugs (P va-
lue was > 0.001 and< 0.05 respectively in prospective and ret-
rospective studies). It is recommended to circumvent
polypharmacy if it is not essential and to report the drug intake
by each child to discover potential sources of heterogeneity be-
tween studies (Smyth et al., 2012; Jua´rez-Olguı´n et al., 2007).
The characteristics which facilitate the development of ADR
in children are comparable to those of adults, nevertheless this
vulnerability is potentiated due to age related divergence in
physiological function, dissimilarity in disease pattern and
smaller size and body weight (Impicciatore et al., 2001). In
our study incidence of ADRs was observed to be the highest
in 0–1 year of age and it was found to be statistically signiﬁcant
in both groups. Further, there are documented evidences that
both the incidence below the age of 1 year and the susceptibility
to death in 0–2 years of age are signiﬁcantly more due to ADRs
(Moore et al., 2002; Aagaard et al., 2010a,b).
Assessment of ADR comes to pass all the time more and
more crucial with ever increasing perception of its conse-
quences in pediatrics, and the development of a customary
authenticated ADR assessment tool for this age group is an
indispensible prerequisite for safe and effective pharmacother-
apy (Du et al., 2012; Aagaard et al., 2010a,b; Carleton et al.,
2009; Vassilev et al., 2009). Du et al., 2012 introduced an
ADR assessment algorithm most suitable for pediatric age.
However, most of the pediatric studies frequently use Nar-
anjo’s algorithm for ADR assessment (Smyth et al., 2012). It
is simple and brief, its validity and reliability have been demon-
strated in adults but not in children (Lamabadusuriya and
Sathiadas, 2003; Weiss et al., 2002). We also used the same
scale in our study for causality assessment and it was revealed
that most of the ADRs belonged to ‘‘possible’’ followed by
‘‘probable’’ category, and ‘‘deﬁnite’’ category, this is similar
to that reported in other recent studies (Napoleone, 2010).
Classiﬁcation and evaluation of ADRs in terms of severity
can recognize the root cause of ADRs and appropriate steps
by healthcare providers can improve pediatric pharmacovigi-
lance (Smyth et al., 2012). It was notable that in our study,
none of the cases was recognized as severe type, and it is
worthwhile to state that there was no mortality due to ADR.
Most of the preventable adverse drug events take place in
the prescribing stage of medication, improper prescribing judg-
ment and inadequate patient monitoring are the most frequent
causes identiﬁed for preventability of adverse drug events. The
median preventability of ADRs in hospitals was reported as
35.2% (18.7–73.2%) (Kanjanarat et al., 2003). Proportions
of augmented ADR 70.3% in retrospective study and 67.3%
in prospective study were observed in our study, which was
in accordance with this study. The type A or augmentedADR is predictable and therefore can be prevented by careful
therapeutic selection of drugs, precedence of this should be ta-
ken by the healthcare providers in order to improve the cost
effectiveness and safety for these illnesses (Lundkvist and
Jo¨nsson, 2004).
The most common class of drugs implicated in our study
was anti infective agents with most common symptoms of
vomiting, diarrhea and skin eruptions, this ﬁnding correlates
with 24 hospitalized studies showing incidence rate of ADRs
within a range of 8.6–100% (Smyth et al., 2012; Clavenna
and Bonati, 2009; dos Santos and Coelho, 2006). The second
most common class of drugs involved was anti epileptic drugs,
producing frequent symptoms like ataxia and drowsiness, this
was consistent with 14 ADR studies of hospitalized pediatric
patients, with incidence rate of 3.9–46.6% reported in a review
study (Smyth et al., 2012).
Moreover, the most frequently affected system by ADRs in
our study was the skin and the symptoms were mild rash, urti-
caria. This was followed by gastrointestinal system and the
symptoms were diarrhea, nausea and vomiting, this was simi-
lar to recent reports (Napoleone, 2010; Priyadharsini et al.,
2011; Aagaard et al., 2010a,b; Clavenna and Bonati, 2009;
dos Santos and Coelho, 2006). Incidence of skin and gastroin-
testinal system ADRs in our both retrospective and prospec-
tive studies were comparable with the range shown by
(Aagaard et al., 2010a,b).
The endeavor of this study is to determine the impact of
intensive monitoring on ﬁnding the improvement of incidence
rate of ADRs. The difference between our two studies was
noteworthy, this highlights the signiﬁcance of intensive pro-
spective collection of ADRs over spontaneous reporting, usual
reminders fails to improve detection, and this is amply evident
from our results. It is highly imperative that more patients can
be brought to record, if we explore for the incidence of ADRs
with a well premeditated approach. Healthcare providers must
be aware of the value of ADR surveillance, scrupulous record-
ing and informing the immediate responsible authority. Cogni-
zance and application of this fact will amplify the coherence of
drug therapy and improve drug safety as well.
Despite the shortcomings of diminutive study interval, pe-
tite sample dimension, limited to a solitary institute and single
department, this study was able to recognize the potential of
active monitoring of ADRs in pharmacovigilance. Speciﬁc
comprehensible causality tool for ADR assessment explicitly
for pediatrics, and reporting of ADR by the patient, in addi-
tion to evidence based treatment approach are crucial for
reducing the incidence of hospitalized ADRs and improve
the pediatric drug safety.
4. Conclusion
Although this study provides preface information, it highlights
the necessity to amplify active monitoring system and encour-
ages more drug safety initiative by healthcare providers to
facilitate safe and effective medication in children.
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